横纹肌肉瘤：儿童肿瘤学组（COG）软组织肉瘤委员会经验回顾及当前 COG 研究的原理。
Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.
机构信息
Department of Pediatrics, Oregon Health and Science University, Portland, Oregon 97239-3098, USA.
出版信息
Pediatr Blood Cancer. 2012 Jul 15;59(1):5-10. doi: 10.1002/pbc.24118. Epub 2012 Feb 29.
Abstract
The prognosis for children and adolescents with rhabdomyosarcoma (RMS) has improved with refinements in multi-modal therapy. Since 1972, the Intergroup Rhabdomyosarcoma Study Group (now the Children's Oncology Group Soft-Tissue Sarcoma Committee) has conducted serial studies for RMS. This review describes the IRSG and COG experience with RMS, presents the current risk stratification definitions, and provides rationale for the current generation of COG RMS studies.
摘要
横纹肌肉瘤（RMS）患儿和青少年的预后随着多模式治疗的改进而得到改善。自 1972 年以来，国际横纹肌肉瘤研究组（现为儿童肿瘤学组软组织肉瘤委员会）已经对 RMS 进行了一系列研究。本综述描述了 IRSG 和 COG 治疗 RMS 的经验，提出了当前的风险分层定义，并为当前一代 COG RMS 研究提供了理论依据。
相似文献
1
Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.横纹肌肉瘤：儿童肿瘤学组（COG）软组织肉瘤委员会经验回顾及当前 COG 研究的原理。
Pediatr Blood Cancer. 2012 Jul 15;59(1):5-10. doi: 10.1002/pbc.24118. Epub 2012 Feb 29.
2
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.局部控制和儿童局限性阴道横纹肌肉瘤的结局：来自儿童肿瘤学组软组织肉瘤委员会的报告。
Pediatr Blood Cancer. 2011 Jul 15;57(1):76-83. doi: 10.1002/pbc.22928. Epub 2011 Feb 4.
3
Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas.儿童肿瘤学组 2023 年研究蓝图：软组织肉瘤。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30556. doi: 10.1002/pbc.30556. Epub 2023 Jul 10.
4
Genitourinary rhabdomyosarcoma: which treatment, how much, and when?泌尿生殖系统横纹肌肉瘤：哪种治疗方法，多少剂量，何时治疗？
J Pediatr Urol. 2009 Dec;5(6):501-6. doi: 10.1016/j.jpurol.2009.06.011. Epub 2009 Jul 28.
5
Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.横纹肌肉瘤研究组III和IV中接受治疗的非转移性横纹肌肉瘤患者的预后因素分析：儿童肿瘤研究组
J Clin Oncol. 2006 Aug 20;24(24):3844-51. doi: 10.1200/JCO.2005.05.3801.
6
Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.横纹肌肉瘤及相关软组织肉瘤的诊断与治疗进展
Cancer Invest. 2000;18(3):223-41. doi: 10.3109/07357900009031827.
7
Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.根据膀胱癌/前列腺横纹肌肉瘤治疗算法的结果比较：来自儿童肿瘤学组、德国软组织肉瘤合作研究组、意大利合作组和国际儿科肿瘤协会恶性间叶肿瘤委员会的联合结果。
Int J Cancer. 2011 Mar 1;128(5):1232-9. doi: 10.1002/ijc.25444.
8
Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies.儿童和青少年新诊断的横纹肌肉瘤转移至骨骼，在儿童肿瘤学组的研究中接受治疗。
Pediatr Blood Cancer. 2024 Oct;71(10):e31200. doi: 10.1002/pbc.31200. Epub 2024 Jul 17.
9
Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.年龄是横纹肌肉瘤的独立预后因素：来自儿童肿瘤学组软组织肉瘤委员会的报告。
Pediatr Blood Cancer. 2004 Jan;42(1):64-73. doi: 10.1002/pbc.10441.
10
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials.横纹肌肉瘤风险分层的最新进展及当前和未来儿童肿瘤学组临床试验的原理。
Pediatr Blood Cancer. 2022 Apr;69(4):e29511. doi: 10.1002/pbc.29511. Epub 2022 Feb 7.
引用本文的文献
1
Two Decades of Outcomes and Quality of Life Following Pencil Beam Scanning Proton Therapy in Children and Adolescents with Rhabdomyosarcoma.横纹肌肉瘤儿童和青少年接受笔形束扫描质子治疗后的二十年预后及生活质量
Cancers (Basel). 2025 Aug 26;17(17):2771. doi: 10.3390/cancers17172771.
2
MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD.肌分化抗原（MyoD）在横纹肌肉瘤中至关重要，它通过分化和CYLD促进细胞存活。
iScience. 2025 Jul 18;28(8):113149. doi: 10.1016/j.isci.2025.113149. eCollection 2025 Aug 15.
3
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition.小儿横纹肌肉瘤中NAPRT的表达及表观遗传调控作为NAMPT抑制的潜在生物标志物
bioRxiv. 2025 Jul 31:2025.07.28.667284. doi: 10.1101/2025.07.28.667284.
4
Vulvar Rhabdomyosarcoma in an Adult Female Patient: A Case Report and Review of Literature.成年女性患者的外阴横纹肌肉瘤：一例病例报告及文献综述
Acta Med Philipp. 2025 Jun 30;59(8):94-101. doi: 10.47895/amp.vi0.9280. eCollection 2025.
5
Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.肺泡横纹肌肉瘤的分子靶点：进展与陷阱的叙述性综述
Int J Mol Sci. 2025 May 28;26(11):5204. doi: 10.3390/ijms26115204.
6
The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group.遗传血统对儿童横纹肌肉瘤生存结局的影响：来自儿童肿瘤学组的报告。
HGG Adv. 2025 Jul 10;6(3):100466. doi: 10.1016/j.xhgg.2025.100466. Epub 2025 Jun 9.
7
Systematic review and meta-analysis of photon radiotherapy versus proton beam therapy for pediatric rhabdomyosarcoma: TRP-rhabdomyosarcoma 2024.儿童横纹肌肉瘤光子放疗与质子束治疗的系统评价和荟萃分析：TRP-横纹肌肉瘤2024。
Int J Clin Oncol. 2025 Jun 10. doi: 10.1007/s10147-025-02794-2.
8
Clinicopathological analysis of 13 patients with embryonal rhabdomyosarcoma of the female reproductive system in the Chinese population.中国人群中13例女性生殖系统胚胎性横纹肌肉瘤患者的临床病理分析
Front Oncol. 2025 Mar 14;15:1546607. doi: 10.3389/fonc.2025.1546607. eCollection 2025.
9
Pediatric head and neck sarcomas: a retrospective study from a national tertiary referral center.儿童头颈部肉瘤：一项来自国家三级转诊中心的回顾性研究。
Eur J Pediatr. 2025 Feb 1;184(2):169. doi: 10.1007/s00431-025-05991-3.
10
Primary Liver Rhabdomyosarcoma with Burnt-out Paravertebral Disease.伴有消退性椎旁疾病的原发性肝横纹肌肉瘤
Indian J Pediatr. 2025 Apr;92(4):402-404. doi: 10.1007/s12098-024-05399-1. Epub 2025 Jan 11.
本文引用的文献
1
Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.D9602 方案即采用长春新碱和放线菌素 D，联合或不联合环磷酰胺和放射治疗，治疗初诊低危胚胎性横纹肌肉瘤患者的结果：儿童肿瘤学组软组织肉瘤委员会的报告。
J Clin Oncol. 2011 Apr 1;29(10):1312-8. doi: 10.1200/JCO.2010.30.4469. Epub 2011 Feb 28.
2
Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.局部控制和儿童局限性阴道横纹肌肉瘤的结局：来自儿童肿瘤学组软组织肉瘤委员会的报告。
Pediatr Blood Cancer. 2011 Jul 15;57(1):76-83. doi: 10.1002/pbc.22928. Epub 2011 Feb 4.
3
Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.1 岁以下婴儿横纹肌肉瘤：儿童肿瘤协作组的报告。
Cancer. 2011 Aug 1;117(15):3493-501. doi: 10.1002/cncr.25887. Epub 2011 Jan 24.
4
Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.随机二期窗口试验研究伊立替康联合长春新碱两种方案治疗横纹肌肉瘤首次复发或进展患者：来自儿童肿瘤协作组的报告。
J Clin Oncol. 2010 Oct 20;28(30):4658-63. doi: 10.1200/JCO.2010.29.7390. Epub 2010 Sep 13.
5
Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.融合基因阴性肺泡横纹肌肉瘤在临床和分子上与胚胎性横纹肌肉瘤无法区分。
J Clin Oncol. 2010 May 1;28(13):2151-8. doi: 10.1200/JCO.2009.26.3814. Epub 2010 Mar 29.
6
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.儿科临床前测试计划对 IGF-1R 单克隆抗体（IMC-A12）的初步测试。
Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6. doi: 10.1002/pbc.22367.
7
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.长春新碱、口服伊立替康和替莫唑胺（VOIT）两种方案治疗复发或难治性实体瘤患儿的 I 期临床试验：儿童肿瘤学组 I 期联盟研究。
Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.
8
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.长春新碱、放线菌素和环磷酰胺与长春新碱、放线菌素和环磷酰胺交替联合长春新碱、拓扑替康和环磷酰胺治疗中危横纹肌肉瘤的疗效比较：儿童肿瘤学组D9803研究
J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21.
9
[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.[F-18]氟脱氧-D-葡萄糖正电子发射断层扫描反应与儿童和青年肢体骨肉瘤的预后相关。
Cancer. 2009 Aug 1;115(15):3519-25. doi: 10.1002/cncr.24421.
10
Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.1973年至2005年监测、流行病学和最终结果计划中成人与儿童横纹肌肉瘤的比较：2600例患者的分析
J Clin Oncol. 2009 Jul 10;27(20):3391-7. doi: 10.1200/JCO.2008.19.7483. Epub 2009 Apr 27.
Zotero 插件